Innate Pharma Files 6-K, Mentions J.P. Morgan Conference
Ticker: IPHYF · Form: 6-K · Filed: Jan 10, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, conference, filing
Related Tickers: IPHA
TL;DR
Innate Pharma filed a 6-K on Jan 10, 2025, mentioning the J.P. Morgan Healthcare Conference.
AI Summary
Innate Pharma S.A. filed a Form 6-K on January 10, 2025, reporting on its activities. The filing references its participation in the 43rd Annual J.P. Morgan Healthcare Conference and includes a quotation from CEO Jonathan Dickinson.
Why It Matters
This filing provides an update on Innate Pharma's corporate activities and its presence at a key industry event, potentially signaling strategic discussions or progress.
Risk Assessment
Risk Level: low — The filing is a routine report of foreign private issuer activities and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- January 10, 2025 (date) — Filing date
- 43rd Annual J.P. Morgan Healthcare Conference (event) — Mentioned in filing
- Jonathan Dickinson (person) — CEO and Chairman of the Executive Board
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report on the activities of Innate Pharma S.A. as a foreign private issuer, including its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on January 10, 2025.
Who is Jonathan Dickinson in relation to Innate Pharma S.A.?
Jonathan Dickinson is the Chief Executive Officer and Chairman of the Executive Board of Innate Pharma S.A.
Does Innate Pharma S.A. file annual reports under Form 20-F or Form 40-F?
Innate Pharma S.A. files annual reports under Form 20-F, as indicated by the checkmark in the filing.
What is the principal executive office address of Innate Pharma S.A.?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Stats: 284 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2025-01-10 06:01:29
Filing Documents
- a6k-iphx250110.htm (6-K) — 10KB
- exhibit991-250110.htm (EX-99.1) — 24KB
- 0001598599-25-000003.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date January 10, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive Officer